It has been engineered for optimal pharmacokinetic properties, including high oral bioavailability, an extended half-life, broad tissues distribution, and the ability to penetrate the central nervous system.378 In preclinical evaluations, adagrasib demonstrated robust inhibition of KRAS-dependent signaling pathways and potent anti-tumor activity across various models derived from KRAS-G12C cell lines and PDXs.368. Here, KRAS is linked to neoplasm.